Core Insights - IMUNON has achieved a significant milestone by reaching data lock for the OVATION 2 Study, which evaluates the safety and efficacy of IMNN-001 in patients with advanced ovarian cancer [2][6] - The study aims to provide insights for the design of a future Phase 3 trial, focusing on primary efficacy endpoints such as Progression Free Survival (PFS) and Overall Survival (OS) [7][8] Group 1: Study Overview - The OVATION 2 Study is assessing the intraperitoneal administration of IMNN-001 in combination with neoadjuvant chemotherapy for patients newly diagnosed with advanced epithelial ovarian cancer [1][6] - A total of 110 patients were fully enrolled in the study by September 2022, with a randomization of 1:1 for treatment comparison [1][6] - The study has reached a median treatment observation duration of 16 months, as required by the protocol [6] Group 2: Treatment Details - IMNN-001 is administered alongside neoadjuvant chemotherapy, with patients receiving up to 17 doses of 100 mg/m² [1][6] - The treatment strategy is designed to shrink tumors for optimal surgical removal, followed by additional cycles of adjuvant chemotherapy [1][6] Group 3: Expected Outcomes - IMUNON anticipates reporting topline results, including hazard ratios, by the end of July 2024 [6] - The primary efficacy analysis will be based on the Intent to Treat (ITT) population, with secondary endpoints including OS, Objective Response Rate, and Chemotherapy Response Score [7] Group 4: Company Background - IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments using non-viral DNA technology [10][11] - The lead clinical program, IMNN-001, is a DNA-based immunotherapy targeting advanced ovarian cancer, designed to induce the production of cancer-fighting molecules at the tumor site [11]

OVATION 2 is evaluating the dosing, safety, efficacy and biological activity of intraperitoneal administration of IMNN-001 in combination with neoadjuvant chemotherapy (NACT) in patients newly diagnosed with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Treatment in the neoadjuvant period is designed to shrink the tumors as much as possible for optimal surgical removal after three cycles of chemotherapy. Following NACT, patients undergo interval debulking surgery, followed by thr ...

DNA vaccine proof-of-concept study expected to demonstrate an "mRNA better" platform LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapy and evaluating an adaptation of the platform's potential as a next-generation vaccine, announces that the first participants have been treated in the IMNN-101 Phase 1 clinical trial. This proof-of-concept study of IMUNON's proprietary PlaCCine® platform is be ...

LAWRENCEVILLE, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an abstract describing a Phase 2 study with IMNN-001 plus bevacizumab (Avastin®) and neoadjuvant chemotherapy in advanced epithelial ovarian cancer patients has been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in Chicago fr ...

Imunon, Inc. (NASDAQ:IMNN) Q1 2024 Earnings Conference Call May 13, 2024 11:00 AM ET Company Participants Kim Golodetz - Investor Relations, LHA Michael Tardugno - Executive Chairman Stacy Lindborg - Chief Executive and President Kursheed Anwer - Chief Science Officer Sebastien Hazard - Chief Medical Officer Jeff Church - Chief Financial Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Kemp Dolliver - Brookline Capital Markets James Molloy - Alliance Global Partners Operator Good morning. ...

Proof-of-concept study for Imunon's first vaccine utilizing its proprietary PlaCCine platform is now open for enrollment Topline results expected this year LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced that DM Clinical Research in Philadelphia is the first site activated and ready for patient recruitment for its Phase 1 study w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-15911 Imunon, Inc. (Exact name of Registrant as specified in its charter) Delaware 52-1256615 (State ...

Exhibit 99.1 IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update "Potential key value-creating milestones are upon us. We expect that this summer will be rewarding and busy as we look to improve the treatment paradigm in late-stage ovarian cancer and to offer an "mRNA-better" vaccine platform technology with excellent commercial promise," said Mr. Michael H. Tardugno, IMUNON's Executive Chairman. Dr. Lindborg, a globally recognized biostatistician, has nearly 30 years of pharmac ...

Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced the appointment of Stacy R. Lindborg, Ph.D. as President and Chief Executive Officer, effective May 13, 2024. Dr ...

LAWRENCEVILLE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Monday, May 13, 2024 to discuss financial results for the first quarter ended March 31, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinica ...